# A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

> **NCT01629615** · PHASE2 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01629615
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-10-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629615, "A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01629615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*